PROFILBARU.COM

Lilotomab
Monoclonal antibody
Type	Whole antibody
Source	Mouse
Target	CD37
Clinical data
Other names	Tetulomab, HH1
ATC code	none;
Identifiers
CAS Number	1453362-55-4 1453362-90-7 (lutetium (177Lu) lilotomab satetraxetan);
ChemSpider	none;
UNII	58I6YNR7BV;
KEGG	D12125;

Lilotomab (formerly tetulomab, HH1)^[1] is a murine monoclonal antibody against CD37,^[2] a glycoprotein which is expressed on the surface of mature human B cells.^[3] It was generated at the Norwegian Radium Hospital.^[3]

As of 2016 it was under development by the Norwegian company Nordic Nanovector ASA as a radioimmunotherapeutic in which lilotomab is conjugated to the beta radiation-emitting isotope lutetium-177 by means of a linker called satetraxetan, a derivative of DOTA.^[2] This compound is called ¹⁷⁷Lu-HH1 or lutetium (¹⁷⁷Lu) lilotomab satetraxetan (trade name Betalutin).^[1] As of 2016, a phase 1/2 clinical trial in people with non-Hodgkin lymphoma was underway.^[4]

References

^ ^a ^b "Lutetium (177lu) lilotomab satetraxetan - Nordic Nanovector". Adis Insight. Springer Nature Switzerland AG. Retrieved 1 September 2016.
^ ^a ^b "Recommended INN List 74" (PDF). WHO Drug Information. 29 (3). 2015.
^ ^a ^b Robak T, Robak P (May 2014). "Anti-CD37 antibodies for chronic lymphocytic leukemia". Expert Opinion on Biological Therapy. 14 (5): 651–61. doi:10.1517/14712598.2014.890182. PMID 24555705. S2CID 19987961.
^ "EudraCT Number: 2011-000033-36". EU Clinical Trials Registry. Treatment of lymphoma with targeted internal radiation therapy (Betalutin)
^ "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 112" (PDF). WHO Drug Information. 28 (4): 515. 2014.

Repetto-Llamazares AH, Larsen RH, Mollatt C, Lassmann M, Dahle J (March 2013). "Biodistribution and dosimetry of (177)Lu-tetulomab, a new radioimmunoconjugate for treatment of non-Hodgkin lymphoma". Current Radiopharmaceuticals. 6 (1): 20–7. doi:10.2174/1874471011306010004. PMC 3624777. PMID 23256748.

This antineoplastic or immunomodulatory drug article is a stub. You can help Wikipedia by expanding it.

This monoclonal antibody–related article is a stub. You can help Wikipedia by expanding it.

[Adis-1] "Lutetium (177lu) lilotomab satetraxetan - Nordic Nanovector". Adis Insight. Springer Nature Switzerland AG. Retrieved 1 September 2016.

[INN74-2] "Recommended INN List 74" (PDF). WHO Drug Information. 29 (3). 2015.

[Robak-3] Robak T, Robak P (May 2014). "Anti-CD37 antibodies for chronic lymphocytic leukemia". Expert Opinion on Biological Therapy. 14 (5): 651–61. doi:10.1517/14712598.2014.890182. PMID 24555705. S2CID 19987961.

[4] "EudraCT Number: 2011-000033-36". EU Clinical Trials Registry. Treatment of lymphoma with targeted internal radiation therapy (Betalutin)

[5] "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 112" (PDF). WHO Drug Information. 28 (4): 515. 2014.

[1]

[2]

[3]

[4]

[5]

Lilotomab

References

Further reading